{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:25:26Z","timestamp":1787052326250,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-03024-w","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:29:17Z","timestamp":1787048957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5612-1170","authenticated-orcid":false,"given":"Yusuf","family":"K\u0131r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Haymana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Toros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagdagul Yuksel","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Uflaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl\u015fah Atbiner","family":"Ero\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fenur \u00c7\u0131rak","family":"G\u00fcrsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esile","family":"Boyraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"Akkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safak","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Co\u015fkun","family":"Meri\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nese Ersoz","family":"Gulcelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"3024_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/cimb47100787","volume":"47","author":"E M\u0142ynarska","year":"2025","unstructured":"M\u0142ynarska E, Bojdo K, Bulicz A et al (2025) Obesity as a multifactorial chronic disease: molecular mechanisms, systemic impact, and emerging digital interventions. Curr Issues Mol Biol 47:787. https:\/\/doi.org\/10.3390\/cimb47100787","journal-title":"Curr Issues Mol Biol"},{"key":"3024_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NCD Risk Factor Collaboration","year":"2024","unstructured":"NCD Risk Factor Collaboration (2024) Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403:1027\u20131050. https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2","journal-title":"Lancet"},{"key":"3024_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/CIRCRESAHA.116.308999","volume":"118","author":"PE Scherer","year":"2016","unstructured":"Scherer PE, Hill JA (2016) Obesity, diabetes, and cardiovascular diseases: a compendium. Circ Res 118:1703\u20131705. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308999","journal-title":"Circ Res"},{"key":"3024_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/ijo.2016.87","volume":"40","author":"C LaGrotte","year":"2016","unstructured":"LaGrotte C, Fernandez-Mendoza J, Calhoun SL, Liao D, Bixler EO, Vgontzas AN (2016) The relative association of obstructive sleep apnea, obesity and excessive daytime sleepiness with incident depression: a longitudinal, population-based study. Int J Obes (Lond) 40:1397\u20131404. https:\/\/doi.org\/10.1038\/ijo.2016.87","journal-title":"Int J Obes (Lond)"},{"key":"3024_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.sleh.2017.07.013","volume":"3","author":"RP Ogilvie","year":"2017","unstructured":"Ogilvie RP, Patel SR (2017) The epidemiology of sleep and obesity. Sleep Health 3:383\u2013388. https:\/\/doi.org\/10.1016\/j.sleh.2017.07.013","journal-title":"Sleep Health"},{"key":"3024_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/ph18030399","volume":"18","author":"R Salvador","year":"2025","unstructured":"Salvador R, Moutinho CG, Sousa C, Vinha AF, Carvalho M, Matos C (2025) Semaglutide as a GLP-1 agonist: a breakthrough in obesity treatment. Pharmaceuticals (Basel) 18:399. https:\/\/doi.org\/10.3390\/ph18030399","journal-title":"Pharmaceuticals (Basel)"},{"key":"3024_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7570\/jomes22067","volume":"32","author":"R Sinha","year":"2023","unstructured":"Sinha R, Papamargaritis D, Sargeant JA, Davies MJ (2023) Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. J Obes Metab Syndr 32:25\u201345. https:\/\/doi.org\/10.7570\/jomes22067","journal-title":"J Obes Metab Syndr"},{"key":"3024_CR8","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s40618-025-02700-7","volume":"48","author":"D Tuccinardi","year":"2025","unstructured":"Tuccinardi D, Masi D, Watanabe M et al (2025) Precision obesity medicine: a phenotype-guided framework for pharmacologic therapy across the lifespan. J Endocrinol Invest 48:2761\u20132798. https:\/\/doi.org\/10.1007\/s40618-025-02700-7","journal-title":"J Endocrinol Invest"},{"key":"3024_CR9","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/s41591-026-04397-4","volume":"32","author":"A Ciudin","year":"2026","unstructured":"Ciudin A, Baker JL, Belan\u010di\u0107 A et al (2026) Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update. Nat Med 32:1962\u20131966. https:\/\/doi.org\/10.1038\/s41591-026-04397-4","journal-title":"Nat Med"},{"key":"3024_CR10","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389:2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"3024_CR11","doi-asserted-by":"publisher","first-page":"e2427258","DOI":"10.1001\/jamanetworkopen.2024.27258","volume":"7","author":"MH Chuang","year":"2024","unstructured":"Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC (2024) Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open 7:e2427258. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.27258","journal-title":"JAMA Netw Open"},{"key":"3024_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"K Hunter","year":"2012","unstructured":"Hunter K, H\u00f6lscher C (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13:33. https:\/\/doi.org\/10.1186\/1471-2202-13-33","journal-title":"BMC Neurosci"},{"key":"3024_CR13","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jalz.2013.12.009","volume":"10","author":"C H\u00f6lscher","year":"2014","unstructured":"H\u00f6lscher C (2014) The incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer\u2019s disease. Alzheimers Dement 10:S47\u2013S54. https:\/\/doi.org\/10.1016\/j.jalz.2013.12.009","journal-title":"Alzheimers Dement"},{"key":"3024_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","volume":"65","author":"RH Anderberg","year":"2016","unstructured":"Anderberg RH, Richard JE, Hansson C, Nissbrandt H, Bergquist F, Skibicka KP (2016) GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology 65:54\u201366. https:\/\/doi.org\/10.1016\/j.psyneuen.2015.11.021","journal-title":"Psychoneuroendocrinology"},{"key":"3024_CR15","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016) The glucagon-like peptide 1 receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. Drug Discov Today 21:802\u2013818. https:\/\/doi.org\/10.1016\/j.drudis.2016.01.013","journal-title":"Drug Discov Today"},{"key":"3024_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499\u2013502. https:\/\/doi.org\/10.1093\/clinchem\/18.6.499","journal-title":"Clin Chem"},{"key":"3024_CR17","volume-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","author":"World Health Organization","year":"2000","unstructured":"World Health Organization (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization, Geneva"},{"key":"3024_CR18","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes\u20142025. Diabetes Care 48:S27\u2013S49. https:\/\/doi.org\/10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"key":"3024_CR19","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE et al (2025) 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 46:4359\u20134378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190","journal-title":"Eur Heart J"},{"key":"3024_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606\u2013613. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x","journal-title":"J Gen Intern Med"},{"key":"3024_CR21","first-page":"S460","volume":"27","author":"YE Sari","year":"2016","unstructured":"Sari YE, Kokoglu B, Balcioglu H, Bilge U, Colak E, Unluoglu I (2016) Turkish reliability of the Patient Health Questionnaire-9. Biomed Res India 27:S460\u2013S462","journal-title":"Biomed Res India"},{"key":"3024_CR22","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/00005650-200412000-00006","volume":"42","author":"B L\u00f6we","year":"2004","unstructured":"L\u00f6we B, Un\u00fctzer J, Callahan CM, Perkins AJ, Kroenke K (2004) Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care 42:1194\u20131201. https:\/\/doi.org\/10.1097\/00005650-200412000-00006","journal-title":"Med Care"},{"key":"3024_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193\u2013213. https:\/\/doi.org\/10.1016\/0165-1781(89)90047-4","journal-title":"Psychiatry Res"},{"key":"3024_CR24","first-page":"107","volume":"7","author":"MY A\u011farg\u00fcn","year":"1996","unstructured":"A\u011farg\u00fcn MY, Kara H, Anlar \u00d6 (1996) The validity and reliability of the Pittsburgh Sleep Quality Index. Turk Psikiyatri Derg 7:107\u2013115","journal-title":"Turk Psikiyatri Derg"},{"key":"3024_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5664\/jcsm.8988","volume":"17","author":"JD Edinger","year":"2021","unstructured":"Edinger JD, Arnedt JT, Bertisch SM et al (2021) Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med 17:263\u2013298. https:\/\/doi.org\/10.5664\/jcsm.8988","journal-title":"J Clin Sleep Med"},{"key":"3024_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG (2009) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41:1149\u20131160. https:\/\/doi.org\/10.3758\/BRM.41.4.1149","journal-title":"Behav Res Methods"},{"key":"3024_CR27","volume-title":"World Obesity Atlas 2024","author":"World Obesity Federation","year":"2024","unstructured":"World Obesity Federation (2024) World Obesity Atlas 2024. World Obesity Federation, London"},{"key":"3024_CR28","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1513\/AnnalsATS.202409-923OC","volume":"22","author":"AE Henney","year":"2025","unstructured":"Henney AE, Riley DR, Anson M et al (2025) Comparative efficacy of tirzepatide, liraglutide, and semaglutide in reduction of risk of major adverse cardiovascular events in patients with obstructive sleep apnea and type 2 diabetes: real-world evidence. Ann Am Thorac Soc 22:1042\u20131052. https:\/\/doi.org\/10.1513\/AnnalsATS.202409-923OC","journal-title":"Ann Am Thorac Soc"},{"key":"3024_CR29","doi-asserted-by":"publisher","first-page":"109762","DOI":"10.5493\/wjem.v15.i4.109762","volume":"15","author":"J Bajpai","year":"2025","unstructured":"Bajpai J, Saxena M, Agarwal U, Pradhan A (2025) Dual incretin analogue tirzepatide: SURMOUNTing the challenge of obesity-induced obstructive sleep apnea. World J Exp Med 15:109762. https:\/\/doi.org\/10.5493\/wjem.v15.i4.109762","journal-title":"World J Exp Med"},{"key":"3024_CR30","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/life15091422","volume":"15","author":"P Carmellini","year":"2025","unstructured":"Carmellini P, Cuomo A, Rescalli MB, Fagiolini A (2025) GLP-1 receptor agonists in mood disorders: a psychiatric perspective. Life (Basel) 15:1422. https:\/\/doi.org\/10.3390\/life15091422","journal-title":"Life (Basel)"},{"key":"3024_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4103\/2230-8210.111625","volume":"17","author":"V Gupta","year":"2013","unstructured":"Gupta V (2013) Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab 17:413\u2013421. https:\/\/doi.org\/10.4103\/2230-8210.111625","journal-title":"Indian J Endocrinol Metab"},{"key":"3024_CR32","doi-asserted-by":"publisher","first-page":"e70661","DOI":"10.1002\/brb3.70661","volume":"15","author":"S Meshkat","year":"2025","unstructured":"Meshkat S, Di Luciano C, Swiderski A et al (2025) Efficacy and safety of glucagon-like peptide-1 agonists for psychiatric symptoms: a systematic review. Brain Behav 15:e70661. https:\/\/doi.org\/10.1002\/brb3.70661","journal-title":"Brain Behav"},{"key":"3024_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","volume":"32","author":"X Chen","year":"2024","unstructured":"Chen X, Zhao P, Wang W, Guo L, Pan Q (2024) The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis. Am J Geriatr Psychiatry 32:117\u2013127. https:\/\/doi.org\/10.1016\/j.jagp.2023.08.010","journal-title":"Am J Geriatr Psychiatry"},{"key":"3024_CR34","doi-asserted-by":"publisher","first-page":"1238353","DOI":"10.3389\/fpsyt.2023.1238353","volume":"14","author":"JR Li","year":"2023","unstructured":"Li JR, Cao J, Wei J, Geng W (2023) Case report: semaglutide-associated depression: a report of two cases. Front Psychiatry 14:1238353. https:\/\/doi.org\/10.3389\/fpsyt.2023.1238353","journal-title":"Front Psychiatry"},{"key":"3024_CR35","doi-asserted-by":"publisher","first-page":"e37928","DOI":"10.1097\/MD.0000000000037928","volume":"103","author":"Y He","year":"2024","unstructured":"He Y, Liang F, Wang Y, Wei Y, Ma T (2024) Liraglutide-associated depression in a patient with type 2 diabetes: a case report and discussion. Med (Baltim) 103:e37928. https:\/\/doi.org\/10.1097\/MD.0000000000037928","journal-title":"Med (Baltim)"},{"key":"3024_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","volume":"207","author":"RB Mansur","year":"2017","unstructured":"Mansur RB, Ahmed J, Cha DS et al (2017) Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord 207:114\u2013120. https:\/\/doi.org\/10.1016\/j.jad.2016.09.056","journal-title":"J Affect Disord"},{"key":"3024_CR37","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3389\/fphar.2020.01270","volume":"11","author":"YK Kim","year":"2020","unstructured":"Kim YK, Kim OY, Song J (2020) Alleviation of depression by glucagon-like peptide-1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function. Front Pharmacol 11:1270. https:\/\/doi.org\/10.3389\/fphar.2020.01270","journal-title":"Front Pharmacol"},{"key":"3024_CR38","doi-asserted-by":"publisher","first-page":"e18491","DOI":"10.1016\/j.heliyon.2023.e18491","volume":"9","author":"Q Ma","year":"2023","unstructured":"Ma Q, Wang L, Liu XX et al (2023) GLP-1 plays a protective role in hippocampal neuronal cells by activating cAMP-CREB-BDNF signaling pathway against CORT\u2009+\u2009HG-induced toxicity. Heliyon 9:e18491. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18491","journal-title":"Heliyon"},{"key":"3024_CR39","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.3390\/ijms262110743","volume":"26","author":"OS Moaket","year":"2025","unstructured":"Moaket OS, Obaid SE, Obaid FE et al (2025) GLP-1 and the degenerating brain: exploring mechanistic insights and therapeutic potential. Int J Mol Sci 26:10743. https:\/\/doi.org\/10.3390\/ijms262110743","journal-title":"Int J Mol Sci"},{"key":"3024_CR40","doi-asserted-by":"publisher","first-page":"106719","DOI":"10.1016\/j.sleep.2025.106719","volume":"134","author":"C Kanu","year":"2025","unstructured":"Kanu C, Shinde S, Chakladar S et al (2025) Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Med 134:106719. https:\/\/doi.org\/10.1016\/j.sleep.2025.106719","journal-title":"Sleep Med"},{"key":"3024_CR41","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12877-025-06547-8","volume":"25","author":"L Shen","year":"2025","unstructured":"Shen L, Jia G, Zhang Y, Xue Z (2025) Association between night sleep duration and depression among Chinese elderly: evidence from the China Health and Retirement Longitudinal Study 2020. BMC Geriatr 25:893. https:\/\/doi.org\/10.1186\/s12877-025-06547-8","journal-title":"BMC Geriatr"},{"key":"3024_CR42","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.3390\/ijms27062853","volume":"27","author":"A Gandhi","year":"2026","unstructured":"Gandhi A, Phyu EM, Koom-Dadzie K, Dickson KB, Halm J (2026) GLP-1 receptor agonists at the crossroads of circadian biology, sleep, and metabolic disease. Int J Mol Sci 27:2853. https:\/\/doi.org\/10.3390\/ijms27062853","journal-title":"Int J Mol Sci"},{"key":"3024_CR43","doi-asserted-by":"publisher","first-page":"e13021","DOI":"10.1111\/apha.13021","volume":"222","author":"V Petrenko","year":"2018","unstructured":"Petrenko V, Dibner C (2018) Cell-specific resetting of mouse islet cellular clocks by glucagon, glucagon-like peptide 1 and somatostatin. Acta Physiol (Oxf) 222:e13021. https:\/\/doi.org\/10.1111\/apha.13021","journal-title":"Acta Physiol (Oxf)"},{"key":"3024_CR44","doi-asserted-by":"publisher","first-page":"116567","DOI":"10.1016\/j.bcp.2024.116567","volume":"230","author":"P Xu","year":"2024","unstructured":"Xu P, Morishige JI, Jing Z et al (2024) Exenatide administration time-dependently affects the hepatic circadian clock through glucagon-like peptide-1 receptors in the central nervous system. Biochem Pharmacol 230:116567. https:\/\/doi.org\/10.1016\/j.bcp.2024.116567","journal-title":"Biochem Pharmacol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03024-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-03024-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03024-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:29:19Z","timestamp":1787048959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-03024-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":44,"alternative-id":["3024"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-03024-w","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of Gulhane Training and Research Hospital (approval no. 2025\/188, dated October 9, 2025).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that the manuscript does not contain any individual person\u2019s identifiable data.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}